Stay updated on Nivolumab & Ipilimumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab & Ipilimumab in Melanoma Clinical Trial page.

Latest updates to the Nivolumab & Ipilimumab in Melanoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe ClinicalTrials.gov page now displays the study record for CheckMate 064, including study design, participant eligibility, treatment arms, and outcome measures, instead of a 403 error.SummaryDifference54%

- Check17 days agoChange DetectedThe site footer revision changed from v3.7.2 to v3.8.0; the study record content remains inaccessible behind a 403 error.SummaryDifference0.2%

- Check24 days agoChange DetectedA site-wide NIH banner announces a transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to related updates and FAQs.SummaryDifference1%

- Check31 days agoChange DetectedThe site footer revision identifier changed from v3.7.1 to v3.7.2 on the error page.SummaryDifference0.2%

- Check38 days agoChange DetectedThe footer revision number was updated from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check59 days agoChange DetectedThe page now displays a 403 Forbidden error with a minimal header, replacing the prior study details with an error notice.SummaryDifference18%

Stay in the know with updates to Nivolumab & Ipilimumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab & Ipilimumab in Melanoma Clinical Trial page.